logo-loader

Shopify bags share price gains after favourable broker research stampede

Shopify shares raced up more than 8% when it became the centre of research attention for brokers at both Wedbush and Mackie on Wednesday

Shopify_001.png
Shopify shares gain as brokers comment

Shopify (NYSE:SHOP) shares raced up more than 8% when it became the centre of research attention for brokers at both Wedbush and Mackie on Wednesday.

Mackie Research reiterated a “Buy” recommendation and maintained the 12-month share price target at $60 on the Ontario-based e-platform.

Mackie described Shopify as “one of the most exciting publicly listed Canadian technology companies we have come across in nearly a decade of following Canadian tech. Q4 results earlier this morning were strong across the board. While operating loss guidance may give some pause, our long-term enthusiasm is undiminished.”

Meanwhile, Wedbush said it was maintaining an Outperform and price target of $50.

Revenue of $130.4mln beat consensus expectations of $121.6mln and was well ahead of the guidance range of $120-$122mln, Wedbush highlighted.

“Merchant count on the SHOP platform grew to 377.5K (better than our expectation of 350K) as sequential net additions reaccelerated to 52K from a previous quarterly run rate of 25K. GMV grew 94% to $5.5 billion and take rate grew to 1.34%, up from 1.3% in Q3 due to increased participation of Shopify Payments by the merchants on the platform,” Wedbush said in a note.

“Company issued revenue guidance for FY17 between $580-600mln representing growth of 51.5% at the midpoint and above consensus expectations of $563.3mln. The company also issued guidance for adjusted operating loss between $(18)-(22) mln,” it added.

Shopify shares were up 8.2% to $60.68.

Staying with tech, Luxoft Holding (NYSE:LXFT) was maintained as an outperform with price target of $67 by brokers at Wedbush.

“FY18's results will feature accelerating organic growth (from 12%), "at least 20%" total revenue growth, while sustaining non-GAAP EBIT margin range (17-19%). We believe recent UBS and Deutsche Bank contract renewals provide management with improving revenue visibility for FY18, while 100%+ Y/Y growth in High Performance Accounts,” Wedbush said in a note on Wednesday.

But Luxoft shares were not so lucky. They were down 4.7% at $57.60 on Wednesday.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 20 hours ago

2 min read